Adimmune

NCT00991224

Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy

NCT02592577

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

NCT02989064

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

NCT03132792

AFPᶜ³³²T in Advanced HCC

NCT03132922

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03391778

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

NCT04044859

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

NCT04526509

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

NCT05943990

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

NCT06048705

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

NCT06204991

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma